Gene expression profiling of the anti-glioma effect of Cilengitide

SpringerPlus

Volumn 2, Issue 1, 2013, Pages

  Onishi, Manabu ^a   Kurozumi, Kazuhiko ^a   Ichikawa, Tomotsugu ^a   Michiue, Hiroyuki ^a   Fujii, Kentaro ^a   Ishida, Joji ^a   Shimazu, Yosuke ^a   Chiocca, E Antonio ^b   Kaur, Balveen ^c   Date, Isao ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Cilengitide; Gene expression profiling; Glioma; Integrin

Indexed keywords

EID: 84876551738     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-160     Document Type: Article

References (43)

1. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Grone HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE (2005) Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11(17):6270-6279. doi:10.1158/1078-0432.CCR-04-1223
2. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B (2006) Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-smallcell lung cancer models. Int J Radiat Oncol Biol Phys 65(5):1536-1543. doi:10.1016/j.ijrobp.2006.04.036
3. Alghisi GC, Ponsonnet L, Ruegg C (2009) The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 4(2):e4449. doi:10.1371/journal.pone.0004449
4. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J (1996) Human ICE/CED-3 protease nomenclature. Cell 87(2):171. doi:S0092-8674(00)81334-3
5. Aoudjit F, Vuori K (2001) Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J Cell Biol 152(3):633-643
6. Brooks PC, Clark RA, Cheresh DA (1994a) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264(5158):569-571
7. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994b) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79(7):1157-1164. doi:0092-8674(94)90007-8
8. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL (2002) Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62(15):4263-4272
9. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY (2000) Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol 46(2):135-144
10. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270(5241):1500-1502
11. Hodivala-Dilke KM, Reynolds AR, Reynolds LE (2003) Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res 314(1):131-144. doi:10.1007/s00441-003-0774-5
12. Husain N, Chiocca EA, Rainov N, Louis DN, Zervas NT (1998) Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol 95(3):287-290
13. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673-687. doi:S0092867402009716
14. Ichii O, Otsuka S, Namiki Y, Hashimoto Y, Kon Y (2011) Molecular pathology of murine ureteritis causing obstructive uropathy with hydronephrosis. PLoS One 6(11):e27783. doi:10.1371/journal.pone.0027783PONE-D-11-14494
15. Kambara H, Okano H, Chiocca EA, Saeki Y (2005) An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65(7):2832-2839. doi:10.1158/0008-5472.CAN-04-3227
16. Kurozumi K, Tamiya T, Ono Y, Otsuka S, Kambara H, Adachi Y, Ichikawa T, Hamada H, Ohmoto T (2004) Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus. J Neurooncol 66(1-2):117-127
17. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, Chiocca EA, Kaur B (2007) Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Canc Inst 99(23):1768-1781. doi:10.1093/jnci/djm229
18. Kurozumi K, Ichikawa T, Onishi M, Fujii K, Date I (2012) Cilengitide treatment for malignant glioma: current status and future direction. Neurol Med Chir (Tokyo) 52(8):539-547. doi:DN/JST.JSTAGE/nmc/52.539
19. Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA (1992) Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 117(5):1101-1107
20. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48(1):151-157
21. Maubant S, Saint-Dizier D, Boutillon M, Perron-Sierra F, Casara PJ, Hickman JA, Tucker GC, Van Obberghen-Schilling E (2006) Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 108(9):3035-3044. doi:10.1182/blood-2006-05-023580
22. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M (2009) Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 11(6):747-756. doi:10.1215/15228517-2009-012
23. Michiue H, Tomizawa K, Matsushita M, Tamiya T, Lu YF, Ichikawa T, Date I, Matsui H (2005a) Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells. FEBS Lett 579(18):3965-3969. doi:10.1016/j.febslet.2005.06.021
24. Michiue H, Tomizawa K, Wei FY, Matsushita M, Lu YF, Ichikawa T, Tamiya T, Date I, Matsui H (2005b) The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction. J Biol Chem 280(9):8285-8289. doi:10.1074/jbc.M412430200
25. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B, Goodman SL (2009) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 124(11):2719-2727. doi:10.1002/ijc.24240
26. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25(13):1651-1657. doi:10.1200/JCO.2006.06.6514
27. Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA (2012) A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. doi:10.1002/cncr.27585
28. Nagata S (1997) Apoptosis by death factor. Cell 88(3):355-365. doi:S0092-8674(00)81874-7
29. Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK (2002) Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 62(22):6764-6769
30. Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, Celik I, Schuch G (2008) Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 27:86. doi:10.1186/1756-9966-27-86
31. Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S, Michiue H, Chiocca EA, Kaur B, Date I (2012) Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology. doi:10.1111/j.1440-1789.2012.01344.x
32. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB (2008a) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26(34):5610-5617. doi:10.1200/JCO.2008.16.7510
33. Reardon DA, Nabors LB, Stupp R, Mikkelsen T (2008b) Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17(8):1225-1235. doi:10.1517/13543784.17.8.1225
34. Schneider-Brachert W, Tchikov V, Neumeyer J, Jakob M, Winoto-Morbach S, Held-Feindt J, Heinrich M, Merkel O, Ehrenschwender M, Adam D, Mentlein R, Kabelitz D, Schutze S (2004) Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21(3):415-428. doi:10.1016/j.immuni.2004.08.017S1074761304002341
35. Stupp R, Weber DC (2005) The role of radio-and chemotherapy in glioblastoma. Onkologie 28(6-7):315-317. doi:10.1159/000085575
36. Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75(6):1169-1178. doi:0092-8674(93)90326-L
37. Tentori L, Dorio AS, Muzi A, Lacal PM, Ruffini F, Navarra P, Graziani G (2008) The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 19(4):1039-1043
38. Tucker GC (2003) Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 4(6):722-731
39. Varner JA, Cheresh DA (1996a) Integrins and cancer. Curr Opin Cell Biol 8(5):724-730. doi:S0955-0674(96)80115-3
40. Varner JA, Cheresh DA (1996b) Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol:69-87
41. Varner JA, Emerson DA, Juliano RL (1995) Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol Biol Cell 6(6):725-740
42. Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, Joachimiak A, Goodman SL, Arnaout MA (2001) Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science 294(5541):339-345. doi:10.1126/science.10645351064535
43. Yoshino K, Motoyama S, Koyota S, Shibuya K, Usami S, Maruyama K, Saito H, Minamiya Y, Sugiyama T, Ogawa J (2011) IGFBP3 and BAG1 enhance radiation-induced apoptosis in squamous esophageal cancer cells. Biochem Biophys Res Commun 404(4):1070-1075. doi:10.1016/j.bbrc.2010.12.115